Author: Tan Doan

Characterising the transmission dynamics of Acinetobacter baumannii in intensive care units using hidden Markov models

Tan N. Doan (1), David C. M. Kong (1), Caroline Marshall (2,3), Carl M. J. Kirkpatrick (1), Emma S. McBryde (2,3)
1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; 2. Victorian Infectious Diseases Service at The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; 3. Department of Medicine, University of Melbourne, Melbourne, Australia

Background: Little is known about the transmission dynamics of Acinetobacter baumannii in hospitals. In the absence of comprehensive epidemiological data, mathematical modelling is an attractive approach to understanding transmission process. The statistical challenge in estimating transmission parameters from infection data arises from the fact that most patients are colonised asymptomatically and therefore the transmission process […]

Read More

Comparison of the probability of target attainment (PTA) of anidulafungin for antifungal prophylaxis against Candida species

Tan Doan (1), David Kong (1), Kashyap Patel (1), Andrew Spencer (2,3), Trish Walker (2), Carl Kirkpatrick (1)
1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Australia; 2. Malignant Haematology and Stem Cell Transplantation Service, Alfred Health, Australia; 3. Faculty of Medicine, Nursing and Health Sciences, Monash University, Australia

Background: Intermittent dosing of anidulafungin is an attractive option for antifungal prophylaxis in patients with acute lymphoblastic leukaemia (ALL) due to anidulafungin’s long half-life and concentration-dependent killing [1]. At present there is a lack of information on the likely PK-PD outcomes of anidulafungin in ALL patients. This study evaluated the probability of target attainment (PTA) […]

Read More